Efficacy and tolerability of zidovudine 200 mg twice a day as part of combination antiretroviral therapy for 96 weeks

Journal of Acquired Immune Deficiency Syndromes

Volumn 54, Issue 5, 2010, Pages

  Duncombe, Chris ^a,b   Kerr, Stephen J ^a,b   Liddy, John ^a   Avihingsanon, Anchalee ^a   Ruxrungtham, Kiat ^a,c   Phanuphak, Praphan ^a,d  

^a THAI RED CROSS AIDS RESEARCH CENTRE   (Thailand)

^b UNIVERSITY OF NEW SOUTH WALES   (Australia)

^c CHULALONGKORN UNIVERSITY   (Thailand)

^d THAI RED CROSS AIDS RESEARCH CENTRE   (Thailand)

Author keywords

[No Author keywords available]

Indexed keywords

HEMOGLOBIN; NONNUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITOR; PROTEINASE INHIBITOR; ZIDOVUDINE;

ANEMIA; BODY WEIGHT; CD4 LYMPHOCYTE COUNT; DRUG EFFICACY; DRUG TOLERABILITY; FEMALE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LETTER; LOW DRUG DOSE; MAJOR CLINICAL STUDY; MALE; NEUTROPENIA; PRIORITY JOURNAL; THAILAND; VIROTHERAPY; VIRUS LOAD;

ADULT; ANTI-HIV AGENTS; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; FEMALE; HIV INFECTIONS; HUMANS; MALE; MEDICATION ADHERENCE; TIME FACTORS; TREATMENT OUTCOME; ZIDOVUDINE;

EID: 77955004081     PISSN: 15254135     EISSN: None     Source Type: Journal    
DOI: 10.1097/QAI.0b013e3181ed1823     Document Type: Letter

References (12)

1. Gilks C. Antiretroviral Therapy for HIV Infection in Adults and Adolescents in Resource-Limited Settings: Towards Universal Access: Recommendations for a Public Health Approach. In press. Geneva, Switzerland: World Health Organization; 2006.
2. Fischl MA, Parker CB, Pettinelli C, et al. A randomized controlled trial of a reduced daily dose of zidovudine in patients with the acquired immunodeficiency syndrome. The AIDS Clinical Trials Group. N Engl J Med. 1990;323:1009-1014.
3. Volberding PA, Lagakos SW, Koch MA, et al. Zidovudine in asymptomatic human immunodeficiency virus infection. A controlled trial in persons with fewer than 500 CD4-positive cells per cubic millimeter. The AIDS Clinical Trials Group of the National Institute of Allergy and Infectious Diseases. N Engl J Med. 1990;322: 941-949.
4. Jost J, Luthy R. Anti-retroviral therapy of HIV-infection. With preliminary results of the Swiss postmarketing surveillance of zidovu-dine. Schweiz Med Wochenschr. 1991;121: 555-565.
5. Koch MA, Volberding PA, Lagakos SW, et al. Toxic effects of zidovudine in asymptomatic human immunodeficiency virus-infected individuals with CD4+ cell counts of 0.50 3 10(9)/L or less. Detailed and updated results from protocol 019 of the AIDS Clinical Trials Group. Arch Intern Med. 1992;152: 2286-2292.
6. Tartaglione TA, Collier AC, Opheim K, et al. Pharmacokinetic evaluations of low-and high-dose zidovudine plus high-dose acyclovir in patients with symptomatic human immunodeficiency virus infection. Antimicrob Agents Chemother. 1991;35: 2225-2231
7. Double blind dose-response study of zidovu-dine in AIDS and advanced HIV infection. Nordic Medical Research Councils' HIV Therapy Group. BMJ. 1992;304:13-17.
8. WHO. Antiretroviral Therapy for HIV Infection in Adults and Adolescents in Resource-Limited Settings: Towards Universal Access: Recommendations for a Public Health Approach. Geneva, Switzerland: World Health Organization; 2006.
9. WHO. WHO Rapid Advice: Antiretroviral Therapy for HIV Infection in Adults and Adolescents. Geneva, Switzerland: World Health Organization; 2009.
10. Ssali F, Stohr W, Munderi P, et al. Prevalence, incidence and predictors of severe anaemia with zidovudine-containing regimens in African adults with HIV infection within the DART trial. Antivir Ther. 2006;11:741-749.
11. Chêne G, Easterbrook P, Juszczak E, et al. Long-term survival in patients with advanced immunodeficiency. AIDS. 1997;11: 209-216.
12. Mocroft A, Kirk O, Barton SE, et al. Anaemia is an independent predictive marker for clinical prognosis in HIV-infected patients from across Europe. EuroSIDA study group. AIDS. 1999; 13:943-950.